Show simple item record

dc.contributor.authorMühlbacher, Axel
dc.contributor.authorJuhnke, Christin
dc.date.accessioned2021-02-10T13:10:09Z
dc.date.available2021-02-10T13:10:09Z
dc.date.issued2016
dc.identifierONIX_20200617_9783954664597_41
dc.identifier46474*
dc.identifierhttp://library.oapen.org/handle/20.500.12657/39700
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/27122
dc.description.abstractThe GKV-VSG introduced for the first time the benefit assessment of examination and treatment methods with medical devices of high classes and invasive character. In the future, the decision on reimbursement will depend on the documentation of benefits and harm. Basically, the benefit assessment can be divided into three phases: measuring the causal effects of an intervention, evaluating the measured effects and deciding on the reimbursement of an aggregate overall benefit. In order to meet the requirements, adaptive study designs, the multi-criteria decision analysis and the adaptive benefit assessment represent a future-proof concept for quick access for patients to innovative treatment methods with high quality and safety.
dc.languageGerman
dc.rightsopen access
dc.subject.classificationbic Book Industry Communication::M Medicine::MB Medicine: general issues::MBN Public health & preventive medicine
dc.subject.otherassessment of benefit
dc.subject.otherstudy design
dc.subject.otherdecision analysis
dc.titleAdaptive Nutzenbewertung für Untersuchungs- und Behandlungsmethoden mit Medizinprodukten hoher Klassen
dc.title.alternativeDie Abwägung von Patientennutzen, Evidenz und Zugang
dc.typebook
oapen.identifier.doi10.32745/9783954664597
oapen.relation.isPublishedByc40cfce7-9c58-4afe-a0f0-974d0995578e
oapen.pages100
oapen.place.publicationBerlin
dc.dateSubmitted2020-06-17T14:18:57Z
dc.abstractotherlanguageThe GKV-VSG introduced for the first time the benefit assessment of examination and treatment methods with medical devices of high classes and invasive character. In the future, the decision on reimbursement will depend on the documentation of benefits and harm. Basically, the benefit assessment can be divided into three phases: measuring the causal effects of an intervention, evaluating the measured effects and deciding on the reimbursement of an aggregate overall benefit. In order to meet the requirements, adaptive study designs, the multi-criteria decision analysis and the adaptive benefit assessment represent a future-proof concept for quick access for patients to innovative treatment methods with high quality and safety.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

open access
Except where otherwise noted, this item's license is described as open access